- Email: [email protected]
8503523 Monoclonal anti-human breast cancer antibodies
345
PATENT ABSTRACTS linked polysaccharide sulfate gel, thereby adsorbing F-HA on the gel, and then eluting FHA from the gel. Said method can give a highly purified F-HA which does not contain any other proteins, lipid, saccharides, etc. and further undesirable endotoxin, and hence can be used for producing various reagents, medicines and pertussis vaccine.
4563423 P R O D U C T S DISPLAYING THE ANTIGENICITY OF HEPATITIS B VIRUS E ANTIGENS AND M E T H O D S OF PRODUCING T H O S E ANTIGENS Kenneth Murray, Patricia MacKay, Heidelberg, Federal Republic Of Germany assigned to BiogenN V Polypeptides displaying the antigenicity of hepatitis B virus e antigens, DNA sequences coding for those polypeptides, antibodies to those polypeptides and methods of producing and using those polypeptides, antibodies and DNA sequences. The polypeptides and antibodies of this invention are characterized by their use in compositions and methods for detecting hepatitis B virus infective carriers and in evaluating the course of HBV-related active liver disease.
4563462 SUBSTANCE AX-2, A PROCESS FOR P R O D U C I N G T H E S A M E AND A N A N T I T U M O R COMPOSITION CONTAINING THE SAME Shinzo Ishii, Shigeo Katsumata, Yuko Arai, Tadashi Ashizawa, Makoto Morimoto, Kunikatsu Shirahata, Yutaka Saito, Motomichi Kono. Shizuoka, Japan assigned to Kyowa Hakko Kogyo Kabushiki A substance designated by us as AX-2 and represented by the formula: See Patent for Chemical Structure This substance is produced by culturing a microorganism of the genus Streptomyces and capable of producing AX-2 in a medium to accumulate AX-2 in the cultured broth and isolating AX-2 therefrom. An antitumor composition comprising an effective amount of AX-2 in association with a physiologically acceptable carrier or excipient, which is active against Sarcoma 180.
8503357 I M P R O V E M E N T S RELATING TO GROWTH FACTORS Michael D WATERFIELD, J SCHLESSINGER, Axel ULLRICH, Imperial Cancer Research Fund, P.O. Box 123, Lincoln's Inn Fields, London WC2A 3PX, United Kingdom assigned to ICRF PATENTS LTD: YEDA RESEARCH & DEVELOPMENT CO LTD; GENENTECH INC Neoplastic and other diseases can be diagnosed by assaying a human test sample e.g. body fluid, tissue or cultured tumour explant ceils, for structurally altered or abnormally expressed growth factor receptors or for the nRNA transcripts of genes which encode them. For example, the assay can be for truncated EGF receptor having at least a portion of its mature amino terminus deleted. Antibodies, capable of binding a predetermined amino acid sequence within the EGF receptor, are also useful in diagnosis and therapy as are conjugates of an immunogenic polymer bound to a polypeptide fragment of EGF receptor. DNA and RNA encoding EGF receptor or fragments thereof are also decribed.
8503508 TOXIN CONJUGATES Lawrence I GREENFIELD. Danute E NITECKI, Donald A KAPLAN, David H GELFAND, Michael PIATAK, Glenn HORN assigned to CETUS CORPORATION Toxin conjugates for selective destruction of target cells. Some embodiments employ spacer peptides between the cytotoxic and binding regions of the conjugates to facilitate translocation and intracellular cleavage after binding to the target cell. Components of the conjugate toxins obtained by recombinant techniques are also described. These components include the spacer peptide and portions of diphtheria toxins and of ricin toxins.
8503523 MONOCLONAL ANTI-HUMAN BREAST CANCER ANTIBODIES Arthur E FRANKEL, David B RING, Michael J BJORN assigned to CETUS CORPORATION
346
PATENT ABSTRACTS
Murine monoclonal antibodies are prepared and characterized which bind selectively to human breast cancer cells, are IgGs or IgMs, and when conjugated to ricin A chain, exhibit a TCID 50% against at least one of MCF-7, CAMA-1, SKBR-3, or BT-20 cells of less than about 10nM. Methods for diagnosing, monitoring, and treating human breast cancer with the antibodies or immunotoxins made therefrom are described.
8503640 LIPOSOME-GEL
COMPOSITIONS
Mircea C POPESCU, Alan L WEINER, Sharon S CARPENTER-GREEN assigned to THE LIPOSOME COMPANY INC; Compositions and methods for maintaining reservoirs of bioactive agents by sequestering the reservoir in a gel matrix. In particular, liposomes containing an entrapped bioactive agent are sequestered in a gel matrix. The resulting liposome-gel compositions may be used in vivo or in vitro to provide for sustained release of the bioactive agent. The gel matrix inhibits the dispersion and clearance of the sequestered liposomes without interfering with the ability of the liposomes to release the entrapped bioactive agent. Furthermore, the rate of release of the bioactive agent from the liposome-gel compositions may be varied by altering the composition of the liposomes and/or gels.
8503705 CRF ANALOGS Catherine Laure RIVIER, Jean Edouard Frederic RIVIER, Wylie Walker Jr VALE, Marvin Ross BROWN assigned to THE SALK INSTITUTE FOR BIOLOGICAL STUDIES Agonists of rCRF and oCRF that can be administered to achieve a substantial elevation of ACTH, beta-endorphin, beta-lipotropin, other products of the pro-opiomelanocortin gene and corticosterone levels and/or a lowering of blood pressure over an extended period of time. One agonist which has been found to be particularly potent is: H-Ser-Gln-Glu-Pro-Pro-Ile-Ser-LeuAsp-Leu-Thr-Phe-His-Leu-Leu-Arg-Glu-MetLeu-Glu-Met-Ala-Lys-Ala-Glu-Gln-Glu-AlaGlu-Gln-Ala-Ala-Leu-Asn-Arg-Leu-Le u-LeuGlu-GIu-Ala-NH)2(. In the agonists, one or more of the first five N-terminal residues may be
deleted or may be substituted by a peptide up to 10 amino acids long and/or by an acylating agent containing up to 7 carbon atoms. A number of other substitutions may also be made throughout the chain. Similar peptides which function as CRF antagonists are created by deleting the first 7, 8 or 9 N-terminal residues. These analogs or pharmaceutically or veterinarily acceptable salts thereof, dispersed in a pharmaceutically or veterinarily acceptable liquid or solid carrier, can be administered to mammals, including humans. The agonists may also be used as stimulants to elevate mood and improve memory and learning, as well as diagnostically. The antagonists can be used to lower stress. 8503724 I M P R O V E M E N T S IN O R RELATING TO THE PRODUCTION OF MALARIA VACCINES lan Allen HOPE, John Graham SCAIFE, Jana STRAMBACHOVA-MCBRIDE, 21 Musgrave Road, Chinnor, Oxford OX9 4PL, United Kingdom assigned to NATIONAL RESEARCH DEVELOPMENT CORPORATION An antigenic materials suitable for use in vaccination against malaria comprises a sequence of amino acid residues present in an antigen occurring in nature in association with intraerythrocytic forms of parasites of the genus Plasmodium, this sequence corresponding to an epitope which is shared with the surface of sporozoites. Such materials may be obtained from nature or synthetically, particularly by genetic engineering techniques, and hybridomas producing an antibody which is specific for the epitope are useful in either approach.
8504103 SYNTHETIC HEPATITIS B VIRUS VACCINE INCLUDING BOTH T CELL ANC B CELL DETERMINANTS David R MILICH, Frank V CHISARI assigned to SCRIPPS CLINIC AND RESEARCH FOUNDATION Chemically synthesized polypeptides include amino acid residue sequences that substantially correspond to the amino acid residue sequences of T cell and B cell determinant portions of a
PATENT ABSTRACTS linked polysaccharide sulfate gel, thereby adsorbing F-HA on the gel, and then eluting FHA from the gel. Said method can give a highly purified F-HA which does not contain any other proteins, lipid, saccharides, etc. and further undesirable endotoxin, and hence can be used for producing various reagents, medicines and pertussis vaccine.
4563423 P R O D U C T S DISPLAYING THE ANTIGENICITY OF HEPATITIS B VIRUS E ANTIGENS AND M E T H O D S OF PRODUCING T H O S E ANTIGENS Kenneth Murray, Patricia MacKay, Heidelberg, Federal Republic Of Germany assigned to BiogenN V Polypeptides displaying the antigenicity of hepatitis B virus e antigens, DNA sequences coding for those polypeptides, antibodies to those polypeptides and methods of producing and using those polypeptides, antibodies and DNA sequences. The polypeptides and antibodies of this invention are characterized by their use in compositions and methods for detecting hepatitis B virus infective carriers and in evaluating the course of HBV-related active liver disease.
4563462 SUBSTANCE AX-2, A PROCESS FOR P R O D U C I N G T H E S A M E AND A N A N T I T U M O R COMPOSITION CONTAINING THE SAME Shinzo Ishii, Shigeo Katsumata, Yuko Arai, Tadashi Ashizawa, Makoto Morimoto, Kunikatsu Shirahata, Yutaka Saito, Motomichi Kono. Shizuoka, Japan assigned to Kyowa Hakko Kogyo Kabushiki A substance designated by us as AX-2 and represented by the formula: See Patent for Chemical Structure This substance is produced by culturing a microorganism of the genus Streptomyces and capable of producing AX-2 in a medium to accumulate AX-2 in the cultured broth and isolating AX-2 therefrom. An antitumor composition comprising an effective amount of AX-2 in association with a physiologically acceptable carrier or excipient, which is active against Sarcoma 180.
8503357 I M P R O V E M E N T S RELATING TO GROWTH FACTORS Michael D WATERFIELD, J SCHLESSINGER, Axel ULLRICH, Imperial Cancer Research Fund, P.O. Box 123, Lincoln's Inn Fields, London WC2A 3PX, United Kingdom assigned to ICRF PATENTS LTD: YEDA RESEARCH & DEVELOPMENT CO LTD; GENENTECH INC Neoplastic and other diseases can be diagnosed by assaying a human test sample e.g. body fluid, tissue or cultured tumour explant ceils, for structurally altered or abnormally expressed growth factor receptors or for the nRNA transcripts of genes which encode them. For example, the assay can be for truncated EGF receptor having at least a portion of its mature amino terminus deleted. Antibodies, capable of binding a predetermined amino acid sequence within the EGF receptor, are also useful in diagnosis and therapy as are conjugates of an immunogenic polymer bound to a polypeptide fragment of EGF receptor. DNA and RNA encoding EGF receptor or fragments thereof are also decribed.
8503508 TOXIN CONJUGATES Lawrence I GREENFIELD. Danute E NITECKI, Donald A KAPLAN, David H GELFAND, Michael PIATAK, Glenn HORN assigned to CETUS CORPORATION Toxin conjugates for selective destruction of target cells. Some embodiments employ spacer peptides between the cytotoxic and binding regions of the conjugates to facilitate translocation and intracellular cleavage after binding to the target cell. Components of the conjugate toxins obtained by recombinant techniques are also described. These components include the spacer peptide and portions of diphtheria toxins and of ricin toxins.
8503523 MONOCLONAL ANTI-HUMAN BREAST CANCER ANTIBODIES Arthur E FRANKEL, David B RING, Michael J BJORN assigned to CETUS CORPORATION
346
PATENT ABSTRACTS
Murine monoclonal antibodies are prepared and characterized which bind selectively to human breast cancer cells, are IgGs or IgMs, and when conjugated to ricin A chain, exhibit a TCID 50% against at least one of MCF-7, CAMA-1, SKBR-3, or BT-20 cells of less than about 10nM. Methods for diagnosing, monitoring, and treating human breast cancer with the antibodies or immunotoxins made therefrom are described.
8503640 LIPOSOME-GEL
COMPOSITIONS
Mircea C POPESCU, Alan L WEINER, Sharon S CARPENTER-GREEN assigned to THE LIPOSOME COMPANY INC; Compositions and methods for maintaining reservoirs of bioactive agents by sequestering the reservoir in a gel matrix. In particular, liposomes containing an entrapped bioactive agent are sequestered in a gel matrix. The resulting liposome-gel compositions may be used in vivo or in vitro to provide for sustained release of the bioactive agent. The gel matrix inhibits the dispersion and clearance of the sequestered liposomes without interfering with the ability of the liposomes to release the entrapped bioactive agent. Furthermore, the rate of release of the bioactive agent from the liposome-gel compositions may be varied by altering the composition of the liposomes and/or gels.
8503705 CRF ANALOGS Catherine Laure RIVIER, Jean Edouard Frederic RIVIER, Wylie Walker Jr VALE, Marvin Ross BROWN assigned to THE SALK INSTITUTE FOR BIOLOGICAL STUDIES Agonists of rCRF and oCRF that can be administered to achieve a substantial elevation of ACTH, beta-endorphin, beta-lipotropin, other products of the pro-opiomelanocortin gene and corticosterone levels and/or a lowering of blood pressure over an extended period of time. One agonist which has been found to be particularly potent is: H-Ser-Gln-Glu-Pro-Pro-Ile-Ser-LeuAsp-Leu-Thr-Phe-His-Leu-Leu-Arg-Glu-MetLeu-Glu-Met-Ala-Lys-Ala-Glu-Gln-Glu-AlaGlu-Gln-Ala-Ala-Leu-Asn-Arg-Leu-Le u-LeuGlu-GIu-Ala-NH)2(. In the agonists, one or more of the first five N-terminal residues may be
deleted or may be substituted by a peptide up to 10 amino acids long and/or by an acylating agent containing up to 7 carbon atoms. A number of other substitutions may also be made throughout the chain. Similar peptides which function as CRF antagonists are created by deleting the first 7, 8 or 9 N-terminal residues. These analogs or pharmaceutically or veterinarily acceptable salts thereof, dispersed in a pharmaceutically or veterinarily acceptable liquid or solid carrier, can be administered to mammals, including humans. The agonists may also be used as stimulants to elevate mood and improve memory and learning, as well as diagnostically. The antagonists can be used to lower stress. 8503724 I M P R O V E M E N T S IN O R RELATING TO THE PRODUCTION OF MALARIA VACCINES lan Allen HOPE, John Graham SCAIFE, Jana STRAMBACHOVA-MCBRIDE, 21 Musgrave Road, Chinnor, Oxford OX9 4PL, United Kingdom assigned to NATIONAL RESEARCH DEVELOPMENT CORPORATION An antigenic materials suitable for use in vaccination against malaria comprises a sequence of amino acid residues present in an antigen occurring in nature in association with intraerythrocytic forms of parasites of the genus Plasmodium, this sequence corresponding to an epitope which is shared with the surface of sporozoites. Such materials may be obtained from nature or synthetically, particularly by genetic engineering techniques, and hybridomas producing an antibody which is specific for the epitope are useful in either approach.
8504103 SYNTHETIC HEPATITIS B VIRUS VACCINE INCLUDING BOTH T CELL ANC B CELL DETERMINANTS David R MILICH, Frank V CHISARI assigned to SCRIPPS CLINIC AND RESEARCH FOUNDATION Chemically synthesized polypeptides include amino acid residue sequences that substantially correspond to the amino acid residue sequences of T cell and B cell determinant portions of a